Titre : Fécondostimulants

Fécondostimulants : Questions médicales fréquentes

Termes MeSH sélectionnés :

Angiotensin II Type 2 Receptor Blockers
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Fécondostimulants : Questions médicales les plus fréquentes", "headline": "Fécondostimulants : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Fécondostimulants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-30", "dateModified": "2025-02-24", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Fécondostimulants" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Agents régulateurs de la reproduction", "url": "https://questionsmedicales.fr/mesh/D012102", "about": { "@type": "MedicalCondition", "name": "Agents régulateurs de la reproduction", "code": { "@type": "MedicalCode", "code": "D012102", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.705" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Fécondostimulants féminins", "alternateName": "Fertility Agents, Female", "url": "https://questionsmedicales.fr/mesh/D005300", "about": { "@type": "MedicalCondition", "name": "Fécondostimulants féminins", "code": { "@type": "MedicalCode", "code": "D005300", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.705.552.344" } } }, { "@type": "MedicalWebPage", "name": "Fécondostimulants masculins", "alternateName": "Fertility Agents, Male", "url": "https://questionsmedicales.fr/mesh/D005303", "about": { "@type": "MedicalCondition", "name": "Fécondostimulants masculins", "code": { "@type": "MedicalCode", "code": "D005303", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.705.552.510" } } } ], "about": { "@type": "MedicalCondition", "name": "Fécondostimulants", "alternateName": "Fertility Agents", "code": { "@type": "MedicalCode", "code": "D005299", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "N Chabbert-Buffet", "url": "https://questionsmedicales.fr/author/N%20Chabbert-Buffet", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France. Electronic address: nathalie.chabbert-buffet@aphp.fr." } }, { "@type": "Person", "name": "N Sermondade", "url": "https://questionsmedicales.fr/author/N%20Sermondade", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } }, { "@type": "Person", "name": "E Moreau", "url": "https://questionsmedicales.fr/author/E%20Moreau", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } }, { "@type": "Person", "name": "S Cristofari", "url": "https://questionsmedicales.fr/author/S%20Cristofari", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } }, { "@type": "Person", "name": "N Johnson", "url": "https://questionsmedicales.fr/author/N%20Johnson", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.", "datePublished": "2024-04-18", "url": "https://questionsmedicales.fr/article/38637829", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13054-024-04910-6" } }, { "@type": "ScholarlyArticle", "name": "Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria.", "datePublished": "2024-04-12", "url": "https://questionsmedicales.fr/article/38606848", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5414/CN111247" } }, { "@type": "ScholarlyArticle", "name": "PHARMACOGENETICS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEI) AND ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN CARDIOVASCULAR DISEASES.", "datePublished": "2024-08-16", "url": "https://questionsmedicales.fr/article/39154825", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejphar.2024.176907" } }, { "@type": "ScholarlyArticle", "name": "Reduction of Proteinuria in a Patient With Primary Aldosteronism by Angiotensin II Receptor Blocker Administration.", "datePublished": "2022-11-30", "url": "https://questionsmedicales.fr/article/37908267", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1210/jcemcr/luac021" } }, { "@type": "ScholarlyArticle", "name": "Overdose of angiotensin II receptor blocker in the third trimester of pregnancy: A case report.", "datePublished": "2024-06-20", "url": "https://questionsmedicales.fr/article/39031828", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jog.16003" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Utilisations thérapeutiques", "item": "https://questionsmedicales.fr/mesh/D045506" }, { "@type": "ListItem", "position": 5, "name": "Agents régulateurs de la reproduction", "item": "https://questionsmedicales.fr/mesh/D012102" }, { "@type": "ListItem", "position": 6, "name": "Fécondostimulants", "item": "https://questionsmedicales.fr/mesh/D005299" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Fécondostimulants - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Fécondostimulants", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Fécondostimulants", "description": "Comment diagnostiquer l'infertilité ?\nQuels tests pour évaluer la réserve ovarienne ?\nQuand consulter un spécialiste de la fertilité ?\nQuels signes indiquent un problème d'ovulation ?\nComment évaluer la qualité du sperme ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Fécondostimulants", "description": "Quels symptômes d'infertilité chez la femme ?\nQuels signes d'infertilité chez l'homme ?\nComment reconnaître un déséquilibre hormonal ?\nQuels symptômes d'ovulation irrégulière ?\nQuels symptômes d'une maladie des ovaires ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Fécondostimulants", "description": "Comment prévenir l'infertilité ?\nQuel rôle de l'alimentation sur la fertilité ?\nComment le stress affecte-t-il la fertilité ?\nPourquoi éviter les toxines environnementales ?\nQuel impact de l'âge sur la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Fécondostimulants", "description": "Quels sont les principaux fécondostimulants ?\nComment fonctionne le clomifène ?\nQuand utiliser des gonadotrophines ?\nQuels effets secondaires des fécondostimulants ?\nComment se déroule une stimulation ovarienne ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Fécondostimulants", "description": "Quelles complications des fécondostimulants ?\nComment reconnaître le syndrome d'hyperstimulation ?\nQuels risques de grossesses multiples ?\nQuelles sont les conséquences d'une grossesse multiple ?\nQuels effets à long terme des fécondostimulants ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Fécondostimulants", "description": "Quels facteurs de risque d'infertilité ?\nQuel impact des antécédents familiaux ?\nComment le poids influence-t-il la fertilité ?\nQuel rôle des maladies chroniques ?\nComment l'environnement influence-t-il la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'infertilité ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'infertilité se diagnostique par des tests hormonaux, échographies et analyses de sperme." } }, { "@type": "Question", "name": "Quels tests pour évaluer la réserve ovarienne ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par la mesure de l'hormone antimüllérienne (AMH) et l'échographie." } }, { "@type": "Question", "name": "Quand consulter un spécialiste de la fertilité ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de consulter après un an d'essais infructueux pour les couples de moins de 35 ans." } }, { "@type": "Question", "name": "Quels signes indiquent un problème d'ovulation ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des cycles irréguliers, des règles absentes ou des douleurs pelviennes peuvent indiquer un problème." } }, { "@type": "Question", "name": "Comment évaluer la qualité du sperme ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La qualité du sperme est évaluée par une analyse de sperme, mesurant la concentration et la motilité." } }, { "@type": "Question", "name": "Quels symptômes d'infertilité chez la femme ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des cycles irréguliers, des douleurs pelviennes et des règles absentes." } }, { "@type": "Question", "name": "Quels signes d'infertilité chez l'homme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les signes peuvent inclure des problèmes d'érection, des douleurs testiculaires ou des anomalies du sperme." } }, { "@type": "Question", "name": "Comment reconnaître un déséquilibre hormonal ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'acné, la prise de poids ou des changements d'humeur peuvent indiquer un déséquilibre." } }, { "@type": "Question", "name": "Quels symptômes d'ovulation irrégulière ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des cycles menstruels irréguliers et des douleurs pelviennes peuvent signaler une ovulation irrégulière." } }, { "@type": "Question", "name": "Quels symptômes d'une maladie des ovaires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs pelviennes, des règles irrégulières et des problèmes de fertilité." } }, { "@type": "Question", "name": "Comment prévenir l'infertilité ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un poids santé, éviter le tabac et gérer le stress peuvent aider à prévenir l'infertilité." } }, { "@type": "Question", "name": "Quel rôle de l'alimentation sur la fertilité ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en antioxydants et en acides gras oméga-3 peut améliorer la fertilité." } }, { "@type": "Question", "name": "Comment le stress affecte-t-il la fertilité ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut perturber les cycles hormonaux et affecter l'ovulation, réduisant ainsi la fertilité." } }, { "@type": "Question", "name": "Pourquoi éviter les toxines environnementales ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les toxines peuvent nuire à la qualité du sperme et à la santé reproductive, augmentant le risque d'infertilité." } }, { "@type": "Question", "name": "Quel impact de l'âge sur la fertilité ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé réduit la qualité des ovules et la fertilité, surtout après 35 ans chez les femmes." } }, { "@type": "Question", "name": "Quels sont les principaux fécondostimulants ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux fécondostimulants incluent le clomifène, les gonadotrophines et l'acide folique." } }, { "@type": "Question", "name": "Comment fonctionne le clomifène ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le clomifène stimule l'ovulation en bloquant les récepteurs d'œstrogènes dans l'hypothalamus." } }, { "@type": "Question", "name": "Quand utiliser des gonadotrophines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les gonadotrophines sont utilisées lorsque le clomifène est inefficace ou en cas d'infertilité sévère." } }, { "@type": "Question", "name": "Quels effets secondaires des fécondostimulants ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des bouffées de chaleur, des nausées et des douleurs abdominales." } }, { "@type": "Question", "name": "Comment se déroule une stimulation ovarienne ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La stimulation ovarienne implique des injections de médicaments et un suivi échographique régulier." } }, { "@type": "Question", "name": "Quelles complications des fécondostimulants ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure le syndrome d'hyperstimulation ovarienne et des grossesses multiples." } }, { "@type": "Question", "name": "Comment reconnaître le syndrome d'hyperstimulation ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs abdominales, des nausées et un gain de poids rapide après traitement." } }, { "@type": "Question", "name": "Quels risques de grossesses multiples ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les fécondostimulants augmentent le risque de grossesses multiples, ce qui peut entraîner des complications." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une grossesse multiple ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les grossesses multiples peuvent entraîner des naissances prématurées et des complications pour la mère." } }, { "@type": "Question", "name": "Quels effets à long terme des fécondostimulants ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des risques accrus de cancer ovarien, bien que les données soient limitées." } }, { "@type": "Question", "name": "Quels facteurs de risque d'infertilité ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, des antécédents médicaux, le tabagisme et l'obésité." } }, { "@type": "Question", "name": "Quel impact des antécédents familiaux ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux d'infertilité peuvent augmenter le risque d'infertilité chez les individus." } }, { "@type": "Question", "name": "Comment le poids influence-t-il la fertilité ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un poids excessif ou insuffisant peut perturber les cycles hormonaux et affecter la fertilité." } }, { "@type": "Question", "name": "Quel rôle des maladies chroniques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies comme le diabète ou le syndrome des ovaires polykystiques peuvent affecter la fertilité." } }, { "@type": "Question", "name": "Comment l'environnement influence-t-il la fertilité ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'exposition à des produits chimiques et à des toxines peut nuire à la qualité reproductive." } } ] } ] }

Sources (10000 au total)

ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.

Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blockers (ARB) medications are widely prescribed. We sought to assess how pre-admission use of these medications might impact th... In a post-hoc subgroup analysis of the randomized, placebo-controlled, Angiotensin Therapy for High Output Shock (ATHOS-3) trial, we compared patients with chronic angiotensin-converting enzyme inhibi... We included n = 321 patients, of whom, 270 were ACEi and ARB-unexposed, 29 were ACEi-exposed and 22 ARB-exposed. In ACEi/ARB-unexposed patients, angiotensin-treated patients, compared to placebo, had ... In vasodilatory shock patients, the cardiovascular and biological RAS response to angiotensin-II differed based upon prior exposure to ACEi and ARB medications. ACEi-exposure was associated with incre...

Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria.

Although guidelines recommend the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) in patients with diabetes, hypertension, and albuminuria, their use r... This retrospective cross-sectional study was conducted using data from the Hatyai Hospital database. Adult patients with diabetes, hypertension, and albuminuria were included. Clinical data and labora... Of 4,655 eligible patients, 500 patients were selected. The average age of the patients was 66.3 years, and 59.6% were female. The adherence rate was 72.4%. Multivariate logistic regression analysis f... ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-...

Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

Bradykinin angioedemas are a potentially serious side effect of angiotensin-converting enzyme inhibitors (ACEI) and more controversially of angiotensin II receptor blockers (ARB). Their challenging di... The aim of this study was to determine the prevalence of recurrent angioedema in patients referred for ACEI/ARB-induced bradykinin angioedema, after more than 6 months of drug discontinuation.... We included ACEI/ARB-treated patients referred for angioedema(s) without hives and unresponsive to antihistamines, after they discontinued ACEI/ARB for at least 6 months. Any C1-inhibitor deficiency w... Thirty-eight of 93 patients (41%) with a suspicion of ACEI/ARB-induced bradykinin angioedema still had recurrent angioedema (n = 27) or developed hives (n = 2) or both (n = 9) after 6 months of drug d... In patients referred for acquired angioedema without wheals occurring during ACEI/ARB therapy, 59% finally had a diagnosis of ACEI/ARB-induced bradykinin angioedema whereas 41% were rather diagnosed w...

Angiotensin II receptor blockers are associated with reduced valvular fibrosis in females with aortic stenosis.

Angiotensin receptor blockers (ARBs) may slow down the progression of aortic stenosis (AS), through their antifibrotic effect. Females present more valvular fibrosis than males, thus ARBs may have mor... We included patients who had an aortic valve replacement± coronary bypass grafting between 2006-2013. Patients with missing echocardiographic or histologic data were excluded. Warren-Yong and fibrosis... Among the 1,321 included patients, the vast majority (89%) has severe AS. Patients in the predominant fibrosis group, as compared to the predominant calcium group, were more often females (39 vs 31%, ... In this large series of patients with moderate-severe AS, among females there was a negative association between intake of ARBs and valvular fibrosis. Thus, the possible effects of ARBs may be sex-spe...